Related Experiment Videos
Pyridoxine-dependent seizures: a review
1Department of Neurology, Medical College, Calicut, Kerala 673 008, India. drrajeshram@rediffmail.com
Indian Pediatrics
|July 26, 2003
Summary
Pyridoxine-dependent epilepsy is a rare genetic disorder causing neonatal seizures due to impaired GABA synthesis. Prompt diagnosis via pyridoxine challenge and lifelong treatment are crucial for managing this condition.
Area of Science:
- Neurology
- Genetics
- Biochemistry
Background:
- Pyridoxine-dependent epilepsy (PDE) is a rare autosomal recessive disorder.
- It typically presents as intractable neonatal seizures.
- PDE results from a deficiency in glutamic acid decarboxylase, affecting GABA synthesis.
Purpose of the Study:
- To summarize the clinical presentation and diagnostic approach for pyridoxine-dependent epilepsy.
- To highlight the efficacy of pyridoxine administration in diagnosis and treatment.
- To discuss the long-term management of this condition.
Main Methods:
- Diagnostic confirmation through parenteral pyridoxine injection test.
- Intravenous pyridoxine administration (50-100 mg) to observe seizure discharge subsidence.
- Assessment of therapeutic response to pyridoxine.
Main Results:
- Seizure discharges typically resolve within 2-6 minutes after intravenous pyridoxine.
- The pyridoxine challenge test is highly effective and reproducible.
- Maintenance therapy with pyridoxine is required indefinitely.
Conclusions:
- Pyridoxine-dependent epilepsy requires prompt diagnosis and lifelong treatment.
- Pyridoxine administration is a key diagnostic and therapeutic tool.
- Optimal maintenance dosage of pyridoxine (Vitamin B6) varies (10-200 mg/day).